As the venture capital industry has matured, funds have grown enormously in size, with some firms managing well over billion-dollar pools of capital. In order to effectively and efficiently move such vast sums, these large, institutional venture firms have mostly abandoned seed and early stage deals to place larger, safer bets with companies further along in their life cycle. This downstream, risk-mitigating shift toward later stage deals has negatively impacted the funding of embryonic technologies not only forcing a higher reliance on “angel” investment capital but hampering both innovation and opportunity as well. Hatch exists in the ecological deal niche, the funding gap, between angels and those large venture firms actively and enthusiastically seeking companies which allow for greater involvement and hence superior risk/adjusted returns.